ClinicalTrials.gg
Sign In
CompletedNCT04301752Updated Mar 18, 2020

Cognitive Impairment and Neuropsychiatric Manifestations of Neurobrucellosis

An observational study in Brucellosis, sponsored by Mansoura University Hospital. Completed at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-18.

Sponsored by Mansoura University Hospital · Observational

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
82
Ages
18 Years and older
Sex
All
01

Study summary

Brucellosis is a common zoonotic infection in many parts of the world including the Mediterranean and Middle Eastern countries.

Neurobrucellosis may develop at any stage of disease and may have widely variable manifestations, including encephalitis, meningoencephalitis, radiculitis, myelitis, peripheral and cranial neuropathies, subarachnoid hemorrhage, and psychiatric manifestations.

Read the detailed description

Brucellosis is a common zoonotic infection in many parts of the world including the Mediterranean and Middle Eastern countries.

Neurobrucellosis may develop at any stage of disease and may have widely variable manifestations, including encephalitis, meningoencephalitis, radiculitis, myelitis, peripheral and cranial neuropathies, subarachnoid hemorrhage, and psychiatric manifestations.

The aimed is to shed light to the obscure areas of diagnosis in neurobrucellosis and have detailed general and neurologic features

02

Conditions studied

  • Brucellosis

Browse trials for

Keywords

  • Brucellosis, neuropsychiatric manifestations, cognition
03

In context

Brucellosis

15 studies on the registry are indexed under Brucellosis; 6 are open to participants now.

Browse Brucellosis studies →

Lead sponsor

Mansoura University Hospital is the lead sponsor of 50 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

82 consecutive patients with brucellosis (18 patients with neuropsychiatric manifestations and 64 patients without neuropsychiatric manifestations) were recruited.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients >18 years of age with laboratory-confirmed brucellosis

Exclusion criteria

Exclusion Criteria:

  • Previous neuropsychiatric disease
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
82 participants (actual)
Patient registry
No

Groups and cohorts

  • Neurobrucellosis

    Brucellosis associated with neuropsychiatric manifestations

    Diagnostic Test: MoCA

  • Non-neurobrucellosis

    Brucellosis not associated with neuropsychiatric manifestations

    Diagnostic Test: MoCA

Interventions

  • Diagnostic testMoCA

    Cognitive function was assessed by using MoCA score. Cognitive impairment was considered present when MoCA scores were \<26. Maximum score is 30.

06

What researchers measure

Primary outcomes

  1. MoCA s

    Cognitive function was assessed by using MoCA score. Cognitive impairment was considered present when MoCA scores were \<26 .

    Time frame: 24 hours

07

Study locations

1 site
  • Mansoura University Hospital
    Mansoura, Egypt
08

References and documents

Publications

  • Young EJ. Brucella species. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases. 7th ed. Philadelphia: Churchill Livingstone, 2010:2921-5.
  • Pappas G, Akritidis N, Bosilkovski M, Tsianos E. Brucellosis. N Engl J Med. 2005 Jun 2;352(22):2325-36. doi: 10.1056/NEJMra050570. No abstract available. PubMed 15930423 ↗
  • Finn TB. Brucellosis. In: Cohen J, Powderly WG, eds. Infectious diseases. 2nd ed. New York: Elsevier, 2004:1665-9.
  • Eren S, Bayam G, Ergonul O, Celikbas A, Pazvantoglu O, Baykam N, Dokuzoguz B, Dilbaz N. Cognitive and emotional changes in neurobrucellosis. J Infect. 2006 Sep;53(3):184-9. doi: 10.1016/j.jinf.2005.10.029. Epub 2006 May 2. PubMed 16647757 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2019 to primary completion in Jan 2020, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2020
First posted
Mar 10, 2020
StartActual
Feb 1, 2019
Primary completionActual
Jan 1, 2020
CompletionActual
Mar 1, 2020
Last update
Mar 18, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04301752
Lead sponsor
Mansoura University Hospital
Responsible party
Ahmed Esmael (Assistant Prof of Neurology, Mansoura University Hospital) — Principal investigator
First posted
Mar 10, 2020
Start date
Feb 1, 2019
Primary completion
Jan 1, 2020
Completion
Mar 1, 2020
Last update
Mar 18, 2020

Study contacts

Esmael M Ahmed, MD
principal investigator · Assistant Prof of Neurology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Brucellosis →

Other studies from this sponsor

Mansoura University Hospital

Start the discussion